The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases

Jianjun Gao; Zhaoyan Gu; Zhaoyan Gu

doi:10.3389/fphar.2022.832732

Frontiers in Pharmacology (Mar 2022)

The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases

Jianjun Gao,
Zhaoyan Gu,
Zhaoyan Gu

Affiliations

Jianjun Gao: Department of Nephrology, Chinese PLA Strategic Support Force Characteristic Medical Center, Beijing, China
Zhaoyan Gu: Department of Endocrinology, Second Medical Center, Chinese PLA General Hospital, Beijing, China
Zhaoyan Gu: National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China

DOI: https://doi.org/10.3389/fphar.2022.832732
Journal volume & issue: Vol. 13

Abstract

Read online

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. Accumulating evidence suggests that PPARs may play an important role in the pathogenesis of kidney disease. All three members of the PPAR subfamily, PPARα, PPARβ/δ, and PPARγ, have been implicated in many renal pathophysiological conditions, including acute kidney injury, diabetic nephropathy, and chronic kidney disease, among others. Emerging data suggest that PPARs may be potential therapeutic targets for renal disease. This article reviews the physiological roles of PPARs in the kidney and discusses the therapeutic utility of PPAR agonists in the treatment of kidney disease.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords